Cumulative HIV Viremia during Highly Active Antiretroviral Therapy Is a Strong Predictorof AIDS‐Related Lymphoma
| Autor: | Alexander, Zoufaly, Hans-Jürgen, Stellbrink, Matthias An der, Heiden, Christian, Kollan, Christian, Hoffmann, Jan, van Lunzen, Osamah, Hamouda, C, Fritzsche |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Male
Oncology medicine.medical_specialty HIV Infections Viremia AIDS-related lymphoma Cohort Studies Acquired immunodeficiency syndrome (AIDS) Risk Factors Antiretroviral Therapy Highly Active Germany Internal medicine Humans Immunology and Allergy Medicine Lymphoma AIDS-Related Proportional Hazards Models business.industry Hazard ratio Primary central nervous system lymphoma virus diseases Viral Load medicine.disease Survival Analysis CD4 Lymphocyte Count Lymphoma Non-Hodgkin's lymphoma Infectious Diseases Immunology Female business Viral load |
| Zdroj: | The Journal of Infectious Diseases. 200:79-87 |
| ISSN: | 1537-6613 0022-1899 |
| Popis: | Background. AIDS-related lymphoma contributes to significant morbidity and mortality among human immunodeficiency virus (HIV)―infected patients receiving highly active antiretroviral therapy (HAART). We assessed the predictive role of cumulative HIV viremia and other risk factors in the development of AIDS-related non-Hodgkin lymphoma. Methods. Data from the Clinical Surveillance of HIV Disease (ClinSurv) study, an ongoing, observational, open cohort study of HIV-infected patients from different urban areas in Germany, were analyzed using a Cox proportional hazards model. Results. In the Cox model, which comprised 6022 patients and 27,812 patient-years of follow-up while patients were receiving HAART from 1999 through 2006, cumulative HIV viremia was found to be independently associated with the risk of lymphoma (hazard ratio, [HR], 1.67 [95% confidence interval {CI}, 1.27―2.20]) (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|